1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,222 | 0,263 | 21:58 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21:09 | QLIFE HOLDING AB: Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7 | 1 | Cision News | ||
| Mo | QLIFE HOLDING AB: Qlife prepares for pharmacy testing in Nordic markets | 1 | Cision News | ||
| QLIFE Aktie jetzt für 0€ handeln | |||||
| 15.01. | QLife Holding AB: Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships | 87 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, together with its partner Hipro Biotechnology Co., Ltd. ("Hipro"), announces a major milestone: the Egoo HbA1c... ► Artikel lesen | |
| 23.12.25 | QLife Holding AB: Qlife provides end-year operational update on key issues | 466 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a pioneer in clinical-grade home diagnostics, provides a year-end operational update on key issues.
Diabetes data
Egoo Health has achieved breakthrough... ► Artikel lesen | |
| 16.12.25 | QLife Holding AB: The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established | 220 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") announces an extension of the non-binding Letter of Intent regarding the potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd.... ► Artikel lesen | |
| 16.12.25 | QLife Holding AB: Qlife and Hipro sign exclusive commercial agreement covering Qlife's sale of Hipro products in EU and US markets | 138 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company"), a first mover in clinical-grade home diagnostics, today announced that it has entered into an exclusive commercial agreement with Hipro Biotechnology Co.... ► Artikel lesen | |
| 12.12.25 | QLife Holding AB: Egoo Health powers AI-driven personalized diabetes management in China | 188 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") is proud to announce that its Egoo Health blood testing platform will play a central role in a groundbreaking project launched by Hipro Biotechnology Co.... ► Artikel lesen | |
| 05.12.25 | QLife Holding AB: Qlife's Birmingham PKU clinical trial published with strong results - key milestone toward CE-mark submission and market launch | 126 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") a first mover in clinical-grade home diagnostics, announces publication of the clinical study for PKU children and adolescents under 18 years of age. The... ► Artikel lesen | |
| 14.11.25 | QLife Holding AB: Update on the reverse takeover process - "Red Chip" structure will not be approved by Nasdaq - other structures are pursued | 237 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or "the Company") and Hipro Biotechnology Co., Ltd. ("Hipro") are working on the planned reverse takeover, as announced in press releases on 5 June 2025 and 5 October 2025.... ► Artikel lesen | |
| 12.11.25 | Qlife Holding AB Q3 Sales Decline | 1 | RTTNews | ||
| 12.11.25 | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q3, July - September 2025 | 132 | GlobeNewswire (Europe) | Advancing Integration & Innovation: Building a Diagnostics Powerhouse
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary... ► Artikel lesen | |
| 05.10.25 | QLife Holding AB: The Letter of Intent with Hipro Biotechnology Co., Ltd. regarding reverse takeover has been extended | 102 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") announces an extension of the Letter of Intent regarding a potential reverse takeover (the "Transaction") with Hipro Biotechnology Co., Ltd. ("Hipro"). The... ► Artikel lesen | |
| 22.09.25 | Qlife Holding AB announces the outcome of the exercise of warrants series TO 6 | 1 | Cision News | ||
| 15.09.25 | QLife Holding AB: Qlife announces additional product line and progresses two new tests into clinical trials | 156 | GlobeNewswire (Europe) | Qlife, a first mover in clinical-grade home diagnostics, and its partner Hipro Biotechnology are advancing two additional biomarker tests-nt-proBNP and potassium-into clinical trials targeting Congestive... ► Artikel lesen | |
| 27.08.25 | QLife Holding AB: QLIFE HOLDING AB, Interim Report Q2, April to June 2025 | 242 | GlobeNewswire (Europe) | Towards a merger with a vision
The full report is attached and can also be found here: https://qlifeholding.com/en/investors/finansiella-rapporter
Financial summary - second quarter 2025
Revenue... ► Artikel lesen | |
| 27.08.25 | QLife Holding AB: Progress update on the reverse takeover process between Qlife and Hipro | 184 | GlobeNewswire (Europe) | Gothenburg, Sweden - Qlife Holding AB ("Qlife" or the "Company") and Hipro Biotechnology Co., Ltd. ("Hipro") remain fully committed to completing the transaction announced in the Letter of Intent signed... ► Artikel lesen | |
| 21.08.25 | Qlife Holding AB increases existing credit facility and extends the maturity date | 1 | Cision News | ||
| 21.08.25 | QLIFE HOLDING AB: Qlife together with Birmingham Women's and Children's NHS Foundation Trust achieve positive results for its rare disease self-test PHE product | 2 | Cision News | ||
| 05.06.25 | Qlife Holding AB receives observation status | 266 | GlobeNewswire | Today, June 5, 2025, Qlife Holding AB (the "Company") issued a press release with information that it has entered into a letter of intent for a reverse takeover of Hipro Biotechnology Co., Ltd.,... ► Artikel lesen | |
| 05.06.25 | QLife Holding AB: Qlife enters letter of intent with Hipro Biotechnology Co., Ltd. to join forces through a reverse takeover | 274 | GlobeNewswire (Europe) | Qlife Holding AB ("Qlife" or the "Company") has entered into a non-binding letter of intent ("Letter of Intent") with Hipro Biotechnology Co., Ltd., registration no. 91130100794182204D, ("Hipro") regarding... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 29,340 | -16,65 % | Goldman Sachs senkt Daumen: Deutsche Medizintechniker Carl Zeiss Meditec und Fresenius Medical Care sacken ab | Goldman Sachs streicht die Kaufempfehlung für zwei Medizintechnik-Spezialisten und schlägt damit Anleger in die Flucht: um fünf Prozent rauscht der MDAX-Wert Carl Zeiss Meditec in der Früh in die Tiefe... ► Artikel lesen | |
| FRESENIUS | 48,470 | +1,74 % | Fresenius: Nach 5-Jahres-Hoch - Analysten weiter optimistisch | Der Trading-Tipp des Tages ist diesmal Fresenius. In diesem Jahr läuft es für die Aktie bisher sehr gut. Gestern erreichte das Papier sogar ein 5-Jahres-Hoch. Heute findet sich Fresenius zwar am DAX-Ende... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,110 | +1,10 % | JPMORGAN stuft Siemens Healthineers auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Siemens Healthineers mit einem Kursziel von 61,30 Euro auf "Overweight" belassen. Der Konzernchef sowie der Finanzvorstand hätten... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,490 | +2,35 % | DAX-Check LIVE: Aixtron, BASF, Bayer, Fresenius Medical Care, K+S, SAP, Schaeffler im Fokus | Nach sieben Rekordtagen in Folge haben am Mittwoch am deutschen Aktienmarkt die Verkäufer die Oberhand gewonnen. Der DAX schloss 0,5 Prozent tiefer bei 25.286 Punkten. Nach sieben Rekordtagen in Folge... ► Artikel lesen | |
| GERRESHEIMER | 27,300 | +9,20 % | Elmos, FMC, Gerresheimer, Hensoldt, Hypoport, Zalando: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,480 | +0,69 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| PROGYNY | 25,060 | -1,53 % | Forecasting The Future: 6 Analyst Projections For Progyny | ||
| GENEDX | 101,06 | +1,02 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 23,855 | +2,38 % | Alignment Healthcare stock price target raised to $28 by KeyBanc | ||
| ANTERIS TECHNOLOGIES GLOBAL | 6,680 | +10,23 % | Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic | MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR), a global structural heart company committed... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 30,670 | -0,87 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| UNITEDHEALTH | 301,85 | +1,43 % | Abend-Update: Unitedhealth zündet den Turbo - das darfst du nicht verpassen | ||
| HEARTFLOW | 33,650 | +0,30 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| ECKERT & ZIEGLER | 16,250 | +4,91 % | Eckert & Ziegler: Kursrally oder Widerstand? Charttechnik und Gewinnchancen im Fokus | ||
| BETA BIONICS | 16,740 | +1,70 % | Beta Bionics, Inc.: Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 |
Das Unternehmen QLIFE HOLDING AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,214 Euro und damit -5,31 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu QLIFE HOLDING AB finden Sie auf Wallstreet Online.